Deep vein thrombosis is a frequent manifestation of venous thromboembolism in which there is a blood clot blocking a deep vein.
Clinical findings are important to the diagnosis of deep vein thrombosis but are poor predictors of the presence or severity of thrombosis.
Pulmonary embolism is the blockage of the blood vessels in the lungs usually due to blood clots from the veins, especially veins in the legs and pelvis.
Dyspnea, pleuritic chest pain, syncope and tachypnea occur in most cases of pulmonary embolism.
Massive pulmonary embolism has the prime symptom of dyspnea and systemic arterial hypotension that requires pressor support is the predominant sign.
Patients with acute, low-risk pulmonary embolism (PE) can be safely discharged within 2 days of hospitalization and treated with rivaroxaban out-of-hospital with a low incidence of recurrence, findings of the HoT-PE* study showed.
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Tailored therapy duration with elastic compression stockings based on a patient’s signs and symptoms was noninferior to the standard therapy duration of 24 months in preventing post-thrombotic syndrome (PTS), according to the IDEAL-DVT* study.
In cancer patients with acute symptomatic or incidental venous thromboembolism, oral edoxaban is noninferior to subcutaneous dalteparin in terms of recurrent venous thromboembolism or major bleeding, according to a study.
Clearing blood clot by means of pharmacomechanical catheter-directed thrombolysis, ie, blood clot removal with specialized devices which also deliver fibrinolytic drug directly to the clot, in addition to standard of care with anticoagulation did not lower the risk of developing post-thrombotic syndrome (PTS) as previously believed, but instead, increased the risk of major bleeding in patients with acute proximal deep-vein thrombosis (DVT) compared with anticoagulation alone, according to the ATTRACT* trial.
The noninferiority of edoxaban compared with dalteparin in preventing recurrent venous thromboembolism (VTE) and major bleeding in patients with cancer highlights edoxaban as a potential alternative to low molecular weight heparin (LMWH) in this group of patients, suggests results of the Hokusai VTE-Cancer Study presented at ASH 2017.
Treatment with direct-acting oral anticoagulants (DOACs) was not associated with increased risks of major bleeding or deaths from any cause within 90 days of therapy initiation, when compared with warfarin in adults with newly diagnosed venous thromboembolism (VTE), according to a large real-world study.
Rosuvastatin led to improved coagulation profile, in particular lower levels of factor VIII procoagulant activity (VIII:C), among patients who had venous thrombosis (VT) previously, suggesting that statins could reduce the risk of recurrent VT, according to a study presented at the ISTH 2017 Congress in Berlin, Germany.
Genetic polymorphisms in CYP2C9 and VKORC1 affect the pharmacology and safety of warfarin, and patients with venous thromboembolism (VTE) who carry the said polymorphisms spend more time overanticoagulated, require a lower drug dose and are at increased bleeding risk with the drug, according to a pharmacogenetic subanalysis of the Hokusai VTE trial.
Coronary artery disease is prevalent among patients who have undergone coronary angiography, according to a new Philippine study presented at the recently concluded 2019 Congress of the Asian Pacific Society of Cardiology (APSC 2019). However, the obtained rates remain lower than that in other Asian countries.
About one of 10 patients with myocardial infarction (MI) at a young age present with clinically defined familial hypercholesterolaemia (FH), reports a study. Furthermore, only two-thirds of FH patients have been discharged on high-intensity statin therapy, and several present with elevated low-density lipoprotein cholesterol (LDL-C) at 1 year.